TTK inhibitors like BOS172722 [65] and CFI-402257 [66] have shown promise in cancer treatment, making TTK a potential independent diagnostic biomarker and therapeutic target for specific HCC subtypes. Here, TTK is linked to hepatocellular carcinoma.